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In this video Q & A, we talk to Alan Lopez about the global burden of tobacco-related mortality. Prof Lopez
highlights how this epidemic emerged in the past, and how it is likely to progress in the future. He also discusses
ways in which countries that currently have few or no tobacco-control policies in place can apply measures to
curtail premature mortality.
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Professor Alan Lopez (Figure 1) is currently Melbourne
Laureate Professor and the Rowden-White Chair of
Global Health and Burden of Disease Measurement at
The University of Melbourne. He is also Director of the
Global Burden of Disease Group in the Melbourne
School of Population and Global Health.
Prior to his current role, he held positions at the Uni-
versity of Queensland from 2003 to 2012 as Professor of
Medical Statistics and Population Health, Professor of
Global Health, and Head of the School of Population
Health. Before this, he spent 22 years at the World Health
Organization (WHO) where he was Chief epidemiologist
in WHO’s Tobacco Control Program (1992 to 1995),
Manager of WHO’s Program on Substance Abuse (1996
to 1998), Director of the Epidemiology and Burden of
Disease Unit (1999 to 2001) and Senior Science Advisor
to the Director-General (2002).
He has published seminal research on the Global
Burden of Disease. and with Sir Richard Peto, devel-
oped the Peto–Lopez method, which is widely used to
estimate tobacco-attributable mortality, and has been used
to support policy action. In this interview (Additional
file 1), we talk to Prof Lopez about his work on tobacco-
related mortality, and ways in countries can apply tobacco
control measures to curtail premature mortality.Correspondence: alan.lopez@unimelb.edu.au
The University of Melbourne, Building 379, 207 Bouverie St, Carlton 3053, VIC,
Australia
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1) You have published seminal work with regard to
tobacco-attributable mortality. What led you to suspect
that tobacco has a large impact on life expectancy?
The work on tobacco mortality came out of work that I
was doing when I was a PhD student. I was looking at
mortality rates historically in Australia, and noticed how
they had changed dramatically, particularly for men, and
I wanted to know what was behind this change. The sex
differential in mortality, which is what I was studying,
was about three years at the turn of the century (similar
to the UK and the US) and rose to about eight years in
the mid-1970s. A lot of this had been linked to tobacco,
but it was very difficult to actually pinpoint the impact
of tobacco from what I call ‘national mortality statistics’.
But I knew it was there, and I got very, very interested
in trying to explain these big divergences in sex mortal-
ity differentials, looking at the impact of tobacco.2) What stimulated your specific interest in tobacco-
attributable mortality as compared to general mortality
trends?
As a PhD student, I was looking at all this mortality data
available – and felt there’s a story here – something’s
driving this. However, I was not a qualified or capable
epidemiologist – I was just a student at that stage. But I
had developed a strong interest in not just describing
health trends and mortality, but also in the causes of
death. I also wanted to know what were the ‘causes’ of
those causes of death? What was driving the lung cancer
rate in Australia and comparator countries like the UK?is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stroke, and so on? So I started to read a lot about epi-
demiology and the epidemiology of non-communicable
diseases. That’s how I first came into contact with the
work of Richard Doll and Richard Peto, and read what
they had done.
They’d done a lot of analytical studies, particularly in
the UK with the British doctors who they’d been follow-
ing, at that stage, for about 20 years from a cohort in the
early 1950s. I started to look at their work, and was very
impressed by the quantification of the impact of tobacco
when you looked at it in defined populations – in this
case, the British doctors. But the Americans were doing
the same thing; the American Cancer Society had set up
a large cohort, and they were looking at the causes of in-
dividual deaths and relating them back to what these in-
dividuals had smoked and what they ate and other
things. They were coming up with very, very significant
risks for various diseases caused by tobacco – lung can-
cer, chronic lung disease – and I was very impressed by
this. At the time, I was not doing these kinds of studies,
but I knew that the explanation to the findings of re-
search that I was doing lay in this kind of epidemiology.
So I got extremely interested in not only the broad de-
scriptive trends, but what was causing those trends.
3) What were the trends of tobacco-attributable mortality
20 years ago as compared to today?
Twenty years ago (that is, the early 1990s), we were seeing
several things happening. When you talk about trends,
you need to disaggregate the exposure group. So, firstly,let’s talk about males and females. Women really only
started to smoke in countries like the UK, Australia and
the US after the First World War, perhaps a long time
after the First World War – the 1930s, 1940s. So they
were not yet dying in large numbers in the late 1980s and
early 1990s.
Men, on the other hand, in the UK, Australia and the
US, had been smoking for up to seven decades ,and so
their epidemic was what we call ‘quite mature’. They
were beginning to die in large numbers in the 1960s and
70s, and by the 1990s something like one-third to 40%
of deaths in middle-aged men were due to tobacco.
That’s a massive premature mortality, and reflects the
long delay between populations taking up smoking in
large numbers and then dying from it, also in large num-
bers. In the 1990s, middle-aged women in the UK and
Australia were just beginning to die of tobacco-related
causes – however, not at the same level as men because
they had always smoked less than men. As women
smoked later than men, we were in this very interesting
position where some countries were beginning to see
rapid rises in female smoking-attributable mortality, but
not yet in other countries such as France.
In the 1990s, you could go to countries, like Spain,
Portugal, France, and you would see women smoking
everywhere! But they were young women who were smok-
ing. Their mothers – the older women – did not smoke,
and so at the time there was very, very little tobacco-
attributable mortality among women in these countries.
But we’re beginning to see that now in French, Spanish,
and other southern European women because they’ve now
been smoking long enough to begin to kill themselves in
large numbers.
In developing countries, on the other hand, we didn’t
really see the impact of tobacco in populations. Richard
Peto and I estimated that it was killing about one million
people in developing countries: a few hundred thousand
in China, a few hundred thousand in India, a few hun-
dred thousand, perhaps, in Latin America. But while
these numbers may sound large, they’re much, much less
than what we’re going to see. So the epidemic was at dif-
ferent stages in different population groups – males and
females, developed and developing countries.
4) How do you think the global tobacco-attributed
mortality rates will change in the future?
We’ve seen enough to understand the evolution of the
epidemic. Let’s take developing countries, if I can use
them as a whole. One in two men in developing coun-
tries smoke cigarettes every day. But they’ve only really
been smoking in China and populations like that since
the 1970s or so, which means we’re not yet seeing the
full effects. In fact, we’re not even seeing much of the ef-
fects of tobacco on these populations of males. But we
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in large numbers.
In fact, smoking prevalence has not declined at all –
marginally in China, but it’s very hard to see significant
changes. Still, six out of ten Chinese men smoke; six out
of ten Indonesian men smoke; three or four out of ten
Indian men smoke. These are very, very large popula-
tions, and if they don’t stop smoking – and it’s very hard
to see that that will happen without concerted global to-
bacco control action – then we’ll see large numbers con-
tinuing to smoke, something like what we saw in the US
and the UK, and eventually the same amount of tobacco-
attributable mortality in these populations. But it’s still too
early to see that.
Women, on the other hand, have not taken up smok-
ing, by and large, in developing countries. Still less than
10%, on average, of women in these populations smoke.
They’re a huge target for the tobacco industry, but we
don’t yet see great amounts of smoking, so we’re not
predicting large amounts of tobacco mortality in women
in those countries. We will see it in men, though.
Developed countries over the last two decades, I think,
have been characterised by some fantastic work by to-
bacco control advocates. Whatever country you look at
– particularly the Anglo-Saxon countries (Australia, UK,
US), the effects of tobacco control measures have been
real, and we’ve seen massive declines in smoking con-
sumption and prevalence. In Australia after the Second
World War, something like 70% of men smoked. It was
the same in the UK. Now 15 to 18% of men smoke. So
there have been huge declines as a result of tobacco con-
trol measures. A lot of those have taken place in that
period since 1990, or at least have consolidated. We have
not seen, really, any increases in prevalence during that
period.
5) If tobacco control measures in many developed
countries have been successful, how can these go on to
inform further interventions, particularly in countries
where interventions to combat smoking are rare or do
not exist?
What I would suggest is that they draw on the experi-
ence, the lessons learned, from countries where control
measures have worked. Smoking control can work. We
have seen huge declines in prevalence. We’ve seen huge
declines in consumption. On average, per capita smok-
ing in the UK and Australia was probably 4,000 ciga-
rettes per adult per year in the 1960s, prior to the US
Surgeon General’s report; it’s now about 1,000. So there’s
been a 75% decline in the amount of tobacco consumed.
It can work. It doesn’t mean the problem is over, but
we’ve seen huge declines. I think the lesson for develop-
ing countries is: why did that happen and how can we
translate that knowledge to help curb our epidemics?There are relatively straightforward things that can be
done. It’s difficult to evaluate formally the actual impact
of A versus B versus C as an intervention. But what we
can see is that the cocktail of interventions – which has
to include price rises, that is, increasing taxation, is a
sure way to cut consumption. There needs to be strict
controls on advertising and promotion. Look at the UK
and Australia – you can’t smoke indoors in public places.
Increasingly, it’s very limited where you can smoke. That
kind of public response to limiting the promotion of to-
bacco, the advertising of tobacco, the facility with which
tobacco can be purchased – that is, in vending machines
– or consumed – that is, in public places – all of those re-
strictions together, those interventions, have led to what
we see: the huge decline in tobacco consumption.
It is really up to developing countries to say, “This is
nonsense. We cannot have one in three, one in two of our
population dying from tobacco. We need to do something
about it.”
6) What specific cultural considerations should be
accounted for when planning anti-smoking interventions?
Anywhere where you plan on implementing an interven-
tion, you need to take into account the likelihood of it
working. I think for these [low- and middle-income]
countries to just pick up the legislation or pick up the
advertising controls that other countries like the US or
the UK have used, would be a mistake. They absolutely
need to consider how these interventions can be most
effective when implemented in their population. That
may mean a number of ways of implementing. It may
mean using cultural figures or religious figures who have
more impact in those populations than they might have
in the West. I think these cultural considerations need
to be carefully thought through.
The tobacco industry are right on to that. They know
exactly what it is in these cultures that will press the
buttons to get people to smoke. They’re using them
already, and certainly, tobacco control has to be as intel-
ligent as the industry in respecting, but exploiting cul-
tural considerations.
7) Are there any differences in tobacco-attributable
mortality/morbidity between high- and low-income
countries?
There are a number of differences. Firstly the volume, as
I mentioned earlier. Tobacco currently kills about six
million people a year. I know that sounds ridiculous, but
there would be six million more people alive today, every
year, had tobacco never been discovered. So it kills a lot
of people, but it’s going to kill a lot more people.
Sir Richard Peto and I quantified the amount of death
from tobacco in the 20th century, and we estimated that
tobacco last century killed about a hundred million
Lopez BMC Medicine 2014, 12:162 Page 4 of 5
http://www.biomedcentral.com/1741-7015/12/162people- mostly in developed countries. In this century,
the 21st century, tobacco is going to kill about a billion
people, mostly in developing countries. So the numbers
are quite different. The timing of the epidemics are quite
different. But also the way that tobacco kills people in
developing countries is different to the way that it kills
people in developed countries. What tobacco tends to
do is take large existing hazards in the population and
multiply them up.
In the UK, Australia and the US, those hazards are
mostly around vascular disease. It’s not unimportant as a
cause of cancer, but tobacco kills most people in devel-
oped countries through vascular disease because that’s
the biggest background risk. In developing countries, for
example in China, where the biggest background risk is
chronic obstructive lung disease (COPD, that is, chronic
bronchitis and emphysema) what tobacco does is to take
that risk and multiply it up. So, from the large prospect-
ive studies in developing populations that Richard Peto
and others have done, we can see it’s killing people more
from COPD and cancer than it does from vascular dis-
ease. It doesn’t mean that it won’t kill them in large
numbers from vascular disease, but at the moment it’s
taking other hazards and multiplying them up.
8) How have your findings influenced policy?
It’s always hard to know. One has to be reasonably mod-
est about the difference between creating science and
seeing it implemented. But I do think there have been
some reactions, and reactions in a constructive way.
When I was Chief Epidemiologist in WHO’s Tobacco
Control Program in the early 1990s, I was very dismayed
to see the way that the tobacco industry took what
WHO said – which ought to be a global authority – and
said, “Well, one day WHO says this number of people die
from tobacco, the other day it says some other number!”
This greatly weakened WHO’s effectiveness, in my view,
as being a global leader in tobacco control.
So one of the first things I did was begin to work with
people like Sir Richard Peto on getting the numbers
right and assessing – how much do we know and how
much don’t we know? And what can and cannot be reli-
ably said about the amount of disease burden attribut-
able to tobacco?
Having spent quite a bit of time with Sir Richard and
colleagues doing that, I felt that WHO was in a much
stronger position to base its evidence and advocacy
work, because it had spent quite a lot of time trying to
get the numbers right. If you don’t have confidence in
the numbers, then your policy and advocacy work is go-
ing to be attacked by the tobacco industry, which it was.
That hasn’t happened, or at least it didn’t happen sub-
sequently, as a result of that effort. I’d like to think that
just trying to get the science right, the epidemiologyright, was of great help both to national tobacco control
efforts, but also to global efforts like those being advo-
cated by WHO. Indeed, I think the work that Richard
Peto and I did, and then, more recently, that Chris Murray
and I did, on the burden of disease attributable to tobacco
compared to other risks has helped. The great advantage
of the burden of disease work is that it allows you to com-
pare tobacco burden with blood pressure burden, with
occupation and so on, so that you can get a better appreci-
ation of just how much death and disease burden it is
causing.
That work, I think, has been instrumental in getting
WHO to take tobacco control more seriously. When
Gro Harlem Brundtland became Director General of
WHO in 1998, she was very serious about evidence and
said, “There’s a massive amount of evidence that tobacco
is causing a massive amount of health loss and will
cause a lot more in our lifetime, what should WHO do
about it?” I think that the epidemiology work we did,
though not the only cause, was certainly one of the
drivers for WHO creating its Tobacco Control Initiative
and taking tobacco a lot more seriously – working on
the Framework Convention, leading that Framework
Convention, being much more of a beacon for countries
to look to and say – what should we do and how effect-
ive will it be?
9) In terms of developing countries, have there been any
large-scale cessation strategies and is there any evidence
that these are working?
I think it’s early days. In countries like China, for ex-
ample, Judith Mackay and others have been working for
decades on tobacco reduction. It’s only now that govern-
ments in these countries are beginning to understand
the tsunami of tobacco-related mortality that’s coming
down, so they’re beginning to take some measures. For
example, China is beginning to restrict advertising, al-
though it’s not yet working successfully on taxation, but
we’re going to keep at it. So, we’re beginning to see some
changes. Prevalence is beginning to come down, but falls
have been modest. There’s a long way to go. Going from
65% prevalence of men to 60% is a small victory, but it’s
an initial victory on a long road.
In many other populations, we don’t see a lot of re-
duction in tobacco use. In Indonesia – another large
population – there has been very, very little change in
tobacco use. We see different trends in Latin America –
large populations like Brazil and Mexico do not seem to
be reaching the same levels of prevalence that we saw in
the West and that we see in parts of Asia, like China
and Indonesia in particular.
There is evidence that you can avoid large tobacco
consumption in populations, through interventions. But
there’s not a lot of evidence yet in developing countries
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very much once it’s reached a high level.
10) How do you think tobacco-related diseases will
change in the next twenty years?
They will increase - unless there’s a massive amount of
cessation among those 50% of men who smoke in devel-
oping countries. Something like 900 million – almost
one billion people – smoke every day. If we’re going to
see the same hazards eventually in these populations –
most of which are in developing countries – as we’ve
seen in rich populations, then one in two of those
smokers is going to die from tobacco use. That’s why we
get these very large predictions of one billion smokers
dying this century from tobacco.
It’s very, very difficult to see how this will be avoided,
without huge successful cessation programs. The best
way to kill yourself is to start smoking before you’re 20
and then continue to do so. Then you’ve got a better
than one in two chance of dying prematurely from to-
bacco use. That’s what we see happening wherever we
study it. We see the age of initiation into tobacco, par-
ticularly for males, is getting younger and younger. So
we’re getting more and more cohorts of young males in
developing countries starting to smoke before they’re 20,
and smoking 16–18 cigarettes per day. Large populations
are wealthy enough now to be able to smoke significant
amounts of tobacco, and they’re not stopping. If that’s the
case, then in our lifetime – sometime in the 2020s and
2030s – we’re going to see that annual toll of tobacco rise
from six million to ten million and then it’s going to go
beyond that. By the middle of this century, tobacco –
without any great change in cessation – is probably going
to be killing 12–15 million people a year. These are absurd
numbers! But this is going to happen unless we are suc-
cessful in reducing consumption, particularly in men, and
particularly in developing countries.
11) Where can I find out more?
See references [1-20].
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